SITC Archive Library

The International Society for Biological Therapy of Cancer (iSBTc) 25^th Annual Meeting: Immuno-Oncology Biomarkers 2010 and Beyond: Perspectives from the iSBTc Biomarker Task Force
September 30, 2010
Building 10, Clinical Center
National Institutes of Health Campus
Bethesda, MD

Program Organizers
Lisa H. Butterfield, PhD - University of Pittsburgh
Mary L. (Nora) Disis, MD - University of Washington
Samir N. Khleif, MD - National Cancer Institute (CCR)
Francesco Marincola, MD - National Institutes of Health (CC, DTM)

Program Summary
This symposium aims achieve several goals. One is to define minimum quality standards and procedures for laboratories developing immunologic biomarkers for clinical trial analyses. The second is to discuss development of potency assays and the reporting of immunologic results. Third, review the current data supporting correlations of immunity and clinical outcome, and how knowledge from other fields (other then immunotherapy of cancer) can contribute to cancer immunotherapy. Lastly, determine which novel and high through-put technologies are now appropriate for use in cancer immunotherapy trials.

Target Audience
The target audience for these programs incorporates basic and clinical investigators from academic, regulatory and biopharmaceutical venues. The audience includes clinicians, researchers, students, post-doctoral fellows and allied health professionals.

Presentations and video recordings are available based on permission from presenters.